Evidence map›Paper›PMID 40495575›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia.

Selina M Vattathil, Freida Blostein, Tyne W Miller-Fleming, Lea K Davis, Alzheimer's Disease Genetics Consortium (ADGC), Alzheimer's Disease Neuroimaging Initiative, Thomas S Wingo, Aliza P Wingo

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Clinical Associations and Possible Risk Factors for Affective Neuropsychiatric Symptoms in Older Adults With and Without Cognitive Impairment.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026
    Article
  4. GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Selina M VattathilDepartment of Neurology, University of California, Davis, Sacramento, California, USA.
Freida BlosteinDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Tyne W Miller-FlemingDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Lea K DavisDivision of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Alzheimer's Disease Genetics Consortium (ADGC)
Alzheimer's Disease Neuroimaging Initiative
Thomas S WingoDepartment of Neurology, University of California, Davis, Sacramento, California, USA.
Aliza P WingoDepartment of Psychiatry, University of California, Davis, Sacramento, California, USA.

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Alzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Genome Wide associate analysis of Alzheimer's DiseaseRC2AG036528 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2010
$5.4M
The brain multi-omic approach to identify key molecular drivers of neuropsychiatric symptoms in Alzheimer's dementiaR01AG072120 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aliza Pham Wingo, Thomas Spurgeon Wingo · 2022 to 2026
$4.3M
Integrative genomic, transcriptomic, and proteomic analyses to investigate sex-specific differences in Alzheimer's DiseaseR01AG075827 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aliza Pham Wingo, Thomas Spurgeon Wingo · 2022 to 2026
$3.7M
Air pollution and early signs of dementiaR01AG079170 · NIA · EMORY UNIVERSITY · PI Anke Huels, Thomas Spurgeon Wingo · 2022 to 2026
$3.6M
PsycheMERGE: Leveraging electronic health records and genomics for mental health researchR01MH118233 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI DAVIS, LEA K, SMOLLER, JORDAN W · 2019 to 2022
$3.1M
VGM: Vanderbilt Genomic Medicine Training ProgramT32HG008341 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Nancy J Cox, Joseph F. Peterson · 2016 to 2026
$2.8M
BLRD VA I01 BX005686BLRD VA IK4 BX005219NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NCRR NIH HHS S10 RR025141NCRR NIH HHS UL1 RR024975NHGRI NIH HHS T32 HG008341NIA NIH HHS R01 AG072120NIA NIH HHS R01AG072120NIA NIH HHS R01 AG075827NIA NIH HHS R01AG075827NIA NIH HHS R01 AG079170NIA NIH HHS R01AG079170NIA NIH HHS RC2 AG036528NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG032984NIA NIH HHS U24 AG072122NIMH NIH HHS 1R01MH118233NIMH NIH HHS R01 MH118233Veterans Affairs I01BX005686Veterans Affairs IK4BX005219
6 · The paper itself

Abstract

introductionNeuropsychiatric symptoms in dementia (NPS) collectively refer to behavioral and psychological symptoms affecting individuals with mild cognitive impairment (MCI) or Alzheimer's disease or related dementia (ADRD). NPS are among the most troubling aspects of living with dementia but their treatments have limited efficacy. We aim to investigate genetic variants contributing to NPS to identify new therapeutic targets.

methodsWe performed a genome-wide association study (GWAS) for nine NPS domains measured by the Neuropsychiatric Symptom Inventory Questionnaire (NPI-Q) in 12,800 participants from Alzheimer's Disease Research Centers across the United States. We performed a replication analysis in two independent cohorts.

resultsWe found genome-wide significant signals for agitation, anxiety, apathy, delusions, and hallucinations that were driven by the apolipoprotein E (APOE) ε4 allele. We replicated these findings in ADNI and BioVU cohorts. Mediation analyses revealed that, except for apathy, MCI/ADRD severity only partially mediated the GWAS signals. DISCUSSION: These findings suggest the APOE ε4 allele influences several NPS independently of and beyond its effect on ADRD. HIGHLIGHTS: Neuropsychiatric symptoms (NPS) are common in mild cognitive impairment and dementia. Effective NPS treatments are pressingly needed, and genetic studies can inform treatment targets to develop effective therapeutics. We conducted a genome-wide association study of NPS in over 12,800 individuals and a replication analysis in two independent cohorts. We found apolipoprotein E (APOE) single-nucleotide polymorphisms (SNPs) associated with multiple NPS domains beyond their effects on cognitive impairment.

Indexed as

Alzheimer DiseaseApolipoproteins ECognitive DysfunctionDementiaGenome-Wide Association StudyAgedAged, 80 and overFemaleHumansMaleNeuropsychological TestsPolymorphism, Single NucleotideApolipoproteins EagitationAlzheimer's diseaseanxietyapathyAPOEcognitive impairmentdelusionsdementiagenome‐wide associationhallucinationsneuropsychiatric symptoms in dementia

Identifiers

PMID40495575
PMCPMC12152374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.